18+ Adults only. We do not sell to anyone under 18. Research compounds are supplied for research use only.
PT-141 research: a peptide chain docking to a receptor

PT-141 (bremelanotide): what it is and what the research shows

PT-141, also called bremelanotide, is one of the few peptides in this space that has a regulatory approval behind it. It is also widely misunderstood, often described as a stronger version of the little blue pill. It is not, and the difference matters. Here is what it is, what the trials showed and where the evidence stops.

PT-141 in 60 seconds

  • PT-141 is bremelanotide, a melanocortin receptor agonist closely related to melanotan II.
  • It acts on desire in the brain, not on blood flow, which is how it differs from sildenafil and similar tablets.
  • It was approved in the United States in 2019 for premenopausal women with low sexual desire, based on two phase 3 trials.
  • Common side effects include nausea and flushing, and it can raise blood pressure briefly.

What PT-141 is

Bremelanotide is a small synthetic peptide that activates melanocortin receptors. It is a close relative of melanotan II, the tanning peptide, but it was developed for a different purpose. Its target is in the central nervous system, where melanocortin signalling is involved in sexual desire and arousal.

How it differs from sildenafil

Sildenafil and similar drugs act on blood vessels and help the physical response. PT-141 acts upstream, on the brain pathways involved in desire. That difference is why it was studied in a condition defined by low desire, and also why it is not simply a stronger version of anything else.

What the trials showed

Two randomised phase 3 trials, RECONNECT studies 301 and 302, enrolled 1,267 premenopausal women with hypoactive sexual desire disorder. Women taking bremelanotide had statistically significant increases in sexual desire and reductions in the distress it caused, compared with placebo. The researchers described the safety profile as favourable, with most adverse events mild or moderate. Both trials were funded by the companies that developed the drug, and the average participant was a 39 year old from a US site.

In men, the evidence is thinner. Small early studies tested intranasal PT-141 in men with erectile dysfunction, including alongside sildenafil, but these did not lead to an approved treatment for men.

Side effects and who should avoid it

Nausea was the most common problem in the trials, and flushing and headache also occur. Melanocortin drugs can raise blood pressure for a few hours after a dose, which is why people with uncontrolled high blood pressure or cardiovascular disease are warned off. Because it is related to melanotan II, skin darkening can also occur with repeated use. Anyone on other medication or with a heart condition should speak to a doctor before considering it.

How big was the effect?

Statistically significant is not the same as large. Across the two RECONNECT trials combined, women on bremelanotide scored 0.35 points higher than placebo on the desire domain of the Female Sexual Function Index, a scale that runs from 1.2 to 6.0. Distress about low desire fell by 0.33 points more than on placebo on a 0 to 4 scale. These are real but modest average differences, which is typical of treatments for desire, where individual responses vary widely.

Nausea, flushing and headache each occurred in 10 percent or more of women on bremelanotide in both studies, more than on placebo. The researchers described most adverse events as mild or moderate.

PT-141 and melanotan II are not the same thing

The two are chemical relatives, and that is where the confusion starts. PT-141 was developed and trialled for sexual desire. Melanotan II was developed as a tanning peptide and is sold in an unregulated market. Reports of darker skin and changes to moles are associated with melanotan II, and anyone with a history of skin cancer or unusual moles should speak to a doctor rather than experiment with melanocortin peptides.

Why low desire needs more than a peptide

Low sexual desire has many causes: hormonal changes, sleep, stress, depression, relationship factors and some common medicines including certain antidepressants. The trials enrolled women diagnosed with a specific disorder after other causes were considered. Working out the cause first matters more than reaching for any compound. Our libido guide covers the wider picture.

Questions to take to a doctor

  • Could a medicine I take, or a hormonal or medical condition, be causing this?
  • Is my blood pressure well controlled, and is a melanocortin drug appropriate with it?
  • What are the realistic benefits, given the modest effect sizes in the trials?
  • Is there anything about my skin, moles or medical history that makes this a bad idea?
  • Are other options worth trying first?

Reading claims about PT-141

  • “Works for everyone”: the trials showed modest average differences, and responses vary.
  • “Proven in men”: the human data in men is small and early.
  • “Boosts testosterone”: not what it does; it acts on melanocortin pathways in the brain.
  • “Same as melanotan II”: related, not the same, and with a very different regulatory history.

What the research does not cover

QuestionWhat we know
Premenopausal women with low desireTwo phase 3 trials, approved in the US in 2019
MenSmall early studies only, no approved use
Long-term useLimited long-term data
Postmenopausal womenNot the population studied in the pivotal trials
South AfricaThe compounds we supply are research use only and not registered medicines

The approval is a US one. The PT-141 we supply is sold for research use only, so it should not be read as a registered product here. See our guide to approved, investigational and research use for how to read those labels.

Questions people ask

What is PT-141?

PT-141 is the research name for bremelanotide, a melanocortin receptor agonist related to melanotan II. It acts on desire pathways in the brain rather than on blood flow.

Does PT-141 really work?

In two phase 3 trials of premenopausal women with low sexual desire, bremelanotide significantly increased desire and reduced related distress compared with placebo. Evidence in men and other groups is much thinner.

Is PT-141 safe?

Nausea and flushing are the most common side effects, and it can raise blood pressure briefly. It is not suitable for everyone, so speak to a doctor first.

Is PT-141 the same as melanotan II?

No, but they are closely related. Melanotan II was developed as a tanning peptide, and PT-141 as a treatment for low sexual desire.

Can I buy PT-141 in South Africa?

We supply PT-141 for research use only, not as a registered medicine. Our legal guide explains what that means.

How big is the effect of PT-141?

In two combined phase 3 trials, women on bremelanotide scored 0.35 points higher than placebo on the 1.2 to 6.0 desire domain scale, and distress fell by 0.33 points more on a 0 to 4 scale. These are real but modest average differences.

Does PT-141 work for men?

The human data in men is small and early, including intranasal studies in erectile dysfunction. It is not an approved treatment for men.

Sources

  1. Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019.
  2. Diamond LE, et al. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction. Urology 2005.

This article is for educational purposes only and is not medical advice. The compounds we supply are sold for research use only and are not registered medicines. Our guide to whether peptides are legal in South Africa explains what that means.

For the wider picture, see peptides for libido. Weighing up a related compound? Peptide side effects covers what to watch for.